Cancer, Blood cancer, Marginal zone lymphoma
ADCTADC TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for ZYNLONTA (Loncastuximab Tesirine) (CD19) in Cancer, Blood cancer, Marginal zone lymphoma. The expected timing is based on the latest available company guidance and may change.
5/6/24 Positive initial data from investigator-initiated Ph2 trial. Additional data presentations at ASH medical congresses on 12/8/2024. 6/16/25- Updated Investigator-Initiated trial data. 11/10/25:- PR No update. 03/10/26:- Publication of MZL Ph2 IIT monotherapy data expected between end-2026 and mid-2027. 05/04/26:- MZL IIT ongoing; data publication still expected between end-2026 and mid-2027. 08/13/26:- Updated MZL IIT data were submitted to ASH and will be presented before YE 2026. BTD submission is planned.
Verification
Confirm timing and program details against the company announcement or filing.